Claims for Patent: 8,664,215
✉ Email this page to a colleague
Summary for Patent: 8,664,215
| Title: | Ocular allergy treatments with alcaftadine |
| Abstract: | Compositions, kits, and methods for the treatment or prevention of ocular allergies and inflammation and the symptoms thereof containing alcaftadine or a pharmaceutically acceptable salt thereof. |
| Inventor(s): | Ingerman; Avner (Scarsdale, NY), Janssens; Frans (Bonheiden, BE), Megens; Anton (Beerse, BE), Abelson; Mark B. (Andover, MA) |
| Assignee: | Vistakon Pharmaceuticals, LLC (Jacksonville, FL) |
| Application Number: | 11/690,954 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,664,215 |
| Patent Claims: |
1. A method of treating a clinical symptom of ocular allergy, comprising administering once daily to the eye of a human patient with said clinical symptom of ocular allergy
an ophthalmic composition comprising alcaftadine, its pharmaceutically acceptable salts, or mixtures thereof.
2. The method of claim 1 wherein the ocular allergy is allergic conjunctivitis. 3. The method of claim 1 wherein the ophthalmic composition comprises from about 0.2% to about 0.35% by weight of alcaftadine. 4. A method of preventing ocular itching in a human patient exposed to a conjunctival allergen, comprising administering once daily to the eye of said human patient an ophthalmic composition comprising alcaftadine, its pharmaceutically acceptable salts, or mixtures thereof, wherein prevention comprises inhibiting said ocular itching compared to a non-treated patient. 5. The method of claim 4 wherein the ophthalmic composition comprises from about 0.2% to about 0.35% by weight of alcaftadine. 6. The method of claim 4 wherein the ophthalmic composition comprises about 0.25% by weight of alcaftadine. 7. The method of claim 1 wherein the ophthalmic composition comprises about 0.25% by weight of alcaftadine. 8. The method according to claim 4 wherein said ophthalmic composition comprising alcaftadine is administered prior to exposure to a conjunctival allergen. 9. The method according to claim 4 wherein said ophthalmic composition comprising alcaftadine is administered after exposure to a conjunctival allergen. 10. The method according to claim 4 further comprising preventing conjunctival redness, chemosis, and lid edema in said human patient exposed to said conjunctival allergen wherein prevention comprises inhibiting said conjunctival redness, chemosis, and lid edema. 11. A method of preventing conjunctival redness, chemosis, and lid edema for a period exceeding 16 hours in a human patient exposed to a conjunctival allergen comprising administering once daily to the eye of said human patient an ophthalmic composition comprising alcaftadine, its pharmaceutically acceptable salts, or mixtures thereof, wherein prevention comprises inhibiting said wherein prevention comprises inhibiting said conjunctival redness, chemosis, and lid edema compared to a non-treated patient. |
